Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -108.45% is 88% above its 4-year average of -891.31%, around the middle of its 4-year range (-46107.27%–47820.75%).
32.94% above its 12-month average of -161.71%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2025 (2025-06-30): -124.80%.
EBITDA MARGIN
-108.45%
EBITDA MARGIN AVG TTM
-161.71%
EBITDA MARGIN AVG 3Y
-1390.75%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+32.94%
CURRENT VS 3Y AVG
+92.20%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Apollomics, Inc.
Market Cap
$49.89M
EBITDA Margin
-108.45%
TTM Avg
-161.71%
3Y Avg
-1390.75%
5Y Avg
N/A
Market Cap
$49.90M
EBITDA Margin
-30422.22%
TTM Avg
-16673.71%
3Y Avg
-8702.25%
5Y Avg
-6477.94%
Market Cap
$50.07M
EBITDA Margin
-36.23%
TTM Avg
-36.23%
3Y Avg
-36.23%
5Y Avg
-36.23%
Market Cap
$50.51M
EBITDA Margin
-61570.00%
TTM Avg
-181077.86%
3Y Avg
-90538.93%
5Y Avg
-60359.29%
Market Cap
$50.80M
EBITDA Margin
-203.44%
TTM Avg
-129.78%
3Y Avg
-288.25%
5Y Avg
-438.27%
Market Cap
$50.96M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$48.66M
EBITDA Margin
22.86%
TTM Avg
-25.83%
3Y Avg
-102.29%
5Y Avg
-102.29%
Market Cap
$51.32M
EBITDA Margin
-2290.88%
TTM Avg
-3688.53%
3Y Avg
-3688.53%
5Y Avg
-3177.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apollomics, Inc. (APLM) | $49.89M | -108.45% | -161.71% | -1390.75% | N/A |
| Microbot Medical Inc. (MBOT)vs › | $49.90M | -30422.22% | -16673.71% | -8702.25% | -6477.94% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.07M | -36.23% | -36.23% | -36.23% | -36.23% |
| INmune Bio, Inc. (INMB)vs › | $50.51M | -61570.00% | -181077.86% | -90538.93% | -60359.29% |
| Celularity Inc. (CELU)vs › | $50.80M | -203.44% | -129.78% | -288.25% | -438.27% |
| Envoy Medical, Inc. (COCH)vs › | $50.96M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| Lite Strategy, Inc. (LITS)vs › | $48.66M | 22.86% | -25.83% | -102.29% | -102.29% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.32M | -2290.88% | -3688.53% | -3688.53% | -3177.84% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $47.83M | -11.13% | -19.55% | -13.57% | -11.41% |
Gross Margin
97.0%
EBITDA Margin
-108.5%
Operating Margin
-111.5%
Net Margin
-128.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-06-30 | -124.80% |
| 2024-12-31 | 1069.30% |
| 2024-06-30 | -1429.64% |
| 2023-12-31 | -8494.89% |
| 2023-06-30 | -5250.41% |
| 2022-12-31 | 8263.60% |
| 2022-06-30 | -3768.40% |
| 2021-12-31 | 47820.75% |
| 2021-06-30 | -46107.27% |
